<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973020</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-I-111</org_study_id>
    <nct_id>NCT04973020</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers</brief_title>
  <official_title>A Single-centre, Single-dose, Open-label and Self-control Study to Evaluate the Effect of Efavirenz on Pharmacokinetic of SHR6390 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-center, open, single-dose, self-controlled clinical trial. It is&#xD;
      planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22&#xD;
      , and from Day8 to Day26 take the efavirenz.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a single-center, open, single-dose, self-controlled clinical trial.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose</time_frame>
    <description>Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose</time_frame>
    <description>Maximum observed serum concentration (Cmax)for SHR6390 after Single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-inf ) for SHR6390 after Single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose</time_frame>
    <description>Time to elimination half-life (T1/2) for for SHR6390 after Single dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events and severity of adverse events</measure>
    <time_frame>from Day 1 to Day 34 after the first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390、efavirenz</intervention_name>
    <description>SHR6390 tablet single dose；Efavirenz single dose.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject can communicate well with the researcher, understand and comply with the&#xD;
             requirements of this study, and understand and sign the informed consent;&#xD;
&#xD;
          2. Healthy subjects aged 18~45 (including 18 and 45 years old);&#xD;
&#xD;
          3. Male body weight ≥ 50kg, female body weight ≥ 45kg, body mass index (BMI) within the&#xD;
             range of 19 ~ 26kg /m2 (including 19 and 26 kg/m2) (BMI= weight (kg)/height 2 (m2));&#xD;
&#xD;
          4. The subjects had no fertility plan, took effective contraceptive measures voluntarily,&#xD;
             and could not donate sperm or eggs within 7 months after signing the informed consent&#xD;
             form to the last medication; the serum HCG test of women with fertility must be&#xD;
             negative before the study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anyone who has suffered from any clinical serious disease such as the circulatory&#xD;
             system, endocrine system, nervous system, digestive system, respiratory system,&#xD;
             urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or&#xD;
             any other disease which can affect the study results.&#xD;
&#xD;
          2. Those who have undergone surgery within 6 months before the trial, or plan to perform&#xD;
             surgery during the study period;&#xD;
&#xD;
          3. Those who donated blood or suffered heavy blood loss (≥400 mL), received blood&#xD;
             transfusions, or used blood products within 3 months before enrollment;&#xD;
&#xD;
          4. Have a history of allergies to drugs, food or other substances;&#xD;
&#xD;
          5. Those who have used soft drugs (such as marijuana) within 3 months before the test or&#xD;
             hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the test; Those&#xD;
             with positive results in urine drug abuse screening;&#xD;
&#xD;
          6. Those who have participated in any clinical trials and have taken study drugs within 3&#xD;
             months before the first administration;&#xD;
&#xD;
          7. Those who have taken any medicine within 4 weeks before the first administration&#xD;
             (including prescription medicines, non-prescription medicines, Chinese herbal&#xD;
             medicines, vitamins, calcium tablets and other food supplements), especially the drugs&#xD;
             which have any effect on CYP3A4;&#xD;
&#xD;
          8. Regular drinkers within 6 months before the test, that is, drinking more than 14 units&#xD;
             of alcohol per week (1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine),&#xD;
             and any alcohol-containing products cannot be stopped during the study Those who are&#xD;
             positive for alcohol breath test;&#xD;
&#xD;
          9. Those with any abnormal result (clinically significant) of vital signs, physical&#xD;
             examination, 12-lead electrocardiogram, chest radiograph, abdominal ultrasound, colour&#xD;
             Doppler echocardiography, hematology, clinical chemistry, urinalysis and coagulation;&#xD;
&#xD;
         10. Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is&#xD;
             positive, or treponema pallidum antibody is positive, or human immunodeficiency virus&#xD;
             antibody is positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunmei Yang</last_name>
    <phone>15216761873</phone>
    <email>yangchunmei@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

